Hutchmed Upgraded to Buy Following $1.18 Billion GSK Licensing Deal

Key Facts

1Daiwa upgraded Hutchmed (HCM) to a 'Buy' rating with a new price target of $18.50.

2Hutchmed entered a licensing deal with GSK for cancer therapy HMPL-A830, including a $110 million upfront payment.

3Potential future milestone payments from GSK could total up to $1.185 billion.

In a move reflecting growing confidence in the Chinese biotech sector, Daiwa has upgraded Hutchmed (HCM) to a 'Buy' rating. This optimism follows the company's major licensing agreement with pharmaceutical giant GSK for the development and commercialization of the experimental cancer therapy HMPL-A830. Under the terms of the deal, Hutchmed will receive an upfront cash payment of $110 million, with the potential for additional milestone-based payments totaling up to $1.185 billion.

According to reports, Daiwa set a new price target of $18.50 for the stock, signaling strong upside potential supported by the strategic partnership that grants GSK exclusive rights outside of Greater China. This upgrade comes as other research firms, including Cavendish and Panmure Liberum, maintain positive ratings on the stock, reinforcing sentiment toward the oncology specialist. The agreement provides immediate liquidity and significant future revenue streams contingent on the drug's clinical and commercial success.

Based on available data, updated closing prices for the instruments were unavailable in the database as of September 3, 2026, leaving qualitative trends as the primary market drivers. Investors should watch for clinical updates regarding the experimental therapy as future catalysts for the stock. Additionally, the economic calendar recently noted the National People's Congress in China on August 28, which may influence the broader environment for globally listed Chinese pharmaceutical firms.